State-of-the-art research on "lymphomas: Role of molecular imaging for staging, prognostic evaluation, and treatment response"

Frontiers in Oncology

Volumn 3 SEP, Issue , 2013, Pages

  Kostakoglu, Lale ^a   Cheson, Bruce D ^b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Hodgkin lymphoma; Interim PET; Non Hodgkin lymphoma; PET CT; Response surrogate

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; BIOPSY; BONE MARROW; CANCER STAGING; CHEMOSENSITIVITY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SURVEILLANCE; FOLLOW UP; HISTOLOGY; HUMAN; LYMPHOMA; META ANALYSIS (TOPIC); MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; RISK; SENSITIVITY AND SPECIFICITY; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE;

EID: 84891103254     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00212     Document Type: Article

References (132)

1. Thill R, Neuerburg J, Fabry U, Cremerius U, Wagenknecht G, Hellwig D, et al. Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma. Nuklearmedizin (1997) 36:234-9.
2. Buchmann I, Reinhardt M, Elsner K, Bunjes D, Altehoefer C, Finke J, et al. 2-(fluorine-18)fluoro-2-deoxy-d-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicentertrial. Cancer (2001) 91:889-999. doi:10.1002/1097-0142(20010301)91:5<889::AID-CNCR1078>3.3.CO;2-X
3. Elstrom R, Guan L, Baker G, Nakhoda K, Vergilio JA, Zhuang H, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood (2003) 101:3875-6. doi:10.1182/blood-2002-09-2778
4. Alavi A, Shrikanthan S, Aydin A, Talanow R, Schuster S. Fluorodeoxyglucose-positron-emission tomography findings in mantle cell lymphoma. Clin Lymphoma Myeloma Leuk (2011) 11:261-6. doi:10.1016/j.clml.2011.03.013
5. Brepoels L, Stroobants S, De Wever W, Dierickx D, Vandenberghe P, Thomas J, et al. Positron emission tomography in mantle cell lymphoma. Leuk Lymphoma (2008) 49:1693-701. doi:10.1080/10428190802216707
6. Bodet-Milin C, Touzeau C, Leux C, Sahin M, Moreau A, Maisonneuve H, et al. Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. Eur J Nucl Med Mol Imaging (2010) 37:1633-42. doi:10.1007/s00259-010-1469-2
7. Le Dortz L, De Guibert S, Bayat S, Devillers A, Houot R, Rolland Y, et al. Diagnostic and prognostic impact of (18)F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging (2010) 37. doi:10.1007/s00259-010-1539-5
8. Wöhrer S, Jaeger U, Kletter K, Becherer A, Hauswirth A, Turetschek K, et al. 18F-fluorodeoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol (2006) 17:780-4. doi:10.1093/annonc/mdl014
9. Jerusalem G, Beguin Y, Najjar F, Hustinx R, Fassotte MF, Rigo P, et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol (2001) 12:825-30. doi:10.1023/A:1011169332265
10. Perry C, Herishanu Y, Metzer U, Bairey O, Ruchlemer R, Trejo L, et al. Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. Eur J Haematol (2007) 79:205-9. doi:10.1111/j.1600-0609.2007.00895.x
11. Tsukamoto N, Kojima M, Hasegawa M, Oriuchi N, Matsushima T, Yokohama A, et al. The usefulness of 18F fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and a comparison of 18F-FDG-PET with 67 gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer (2007) 110:652-9.
12. Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I, et al. 18F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med (2010) 51:25-30. doi:10.2967/jnumed.109.067892
13. Kako S, Izutsu K, Ota Y, Minatani Y, Sugaya M, Momose T, et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol (2007) 18:1685-90. doi:10.1093/annonc/mdm265
14. Tan D, Horning SJ. Follicular lymphoma: clinical features and treatment. Hematol Oncol Clin North Am (2008) 22:863-82. doi:10.1016/j.hoc.2008.07.013
15. Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, Amess J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol (2007) 25:2426-33. doi:10.1200/JCO.2006.09.3260
16. Noy A, Schöder H, Gönen M, Weissler M, Ertelt K, Cohler C, et al. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol (2009) 20:508-12. doi:10.1093/annonc/mdn657
17. Schöder H, Noy A, Gönen M, Weng L, Green D, Erdi YE, et al. Intensity of 18 fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol (2005) 23:4643-51. doi:10.1200/JCO.2005.12.072
18. Bruzzi JF, Macapinlac H, Tsimberidou AM, Truong MT, Keating MJ, Marom EM, et al. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med (2006) 47:1267-73.
19. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswald meeting. J Clin Oncol (1989) 7:1630-6.
20. Rosenberg S. Validity of the Ann Arbor staging system classification for the non-Hodgkin's lymphomas. Cancer Treat Rep (1977) 61:1023-7.
21. Nyman R, Forsgren G, Glimelius B. Long-term follow-up of residual mediastinal masses in treated Hodgkin's disease using MR imaging. Acta Radiol (1996) 37:323-6. doi:10.3109/02841859609177659
22. Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluoro-d-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer (2005) 104:1066-74. doi:10.1002/cncr.21253
23. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Merkle E, Frickhofen N, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology (1998) 206:475-81.
24. Hutchings M, Loft A, Hansen M, Pedersen LM, Berthelsen AK, Keiding S, et al. Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica (2006) 91:482-9.
25. Schaefer NG, Hany TF, Taverna C, Seifert B, Stumpe KD, von Schulthess GK, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT? Radiology (2004) 232:823-9. doi:10.1148/radiol.2323030985
26. Naumann R, Beuthien-Baumann B, Reiss A, Schulze J, Hänel A, Bredow J, et al. Substantial impact of FDG-PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer (2004) 90:620-5. doi:10.1038/sj.bjc.6601561
27. Bangerter M, Moog F, Buchmann I, Kotzerke J, Griesshammer M, Hafner M, et al. Whole-body 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol (1998) 9:1117-22. doi:10.1023/A:1008486928190
28. Weihrauch MR, Re D, Bischoff S, Dietlein M, Scheidhauer K, Krug B, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol (2002) 81:20-5. doi:10.1007/s00277-001-0390-y
29. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica (2001) 86:266-73.
30. Picardi M, Soricelli A, Grimaldi F, Nicolai E, Gallamini A, Pane F. Fused FDG-PET/contrast-enhanced CT detects occult subdiaphragmatic involvement of Hodgkin's lymphoma thereby identifying patients requiring six cycles of anthracycline-containing chemotherapy and consolidation radiation of spleen. Ann Oncol (2011) 22:671-80. doi:10.1093/annonc/mdq403
31. Carr R, Barrington SF, Madan B, O'Doherty MJ, Saunders CA, van der Walt J, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood (1998) 91:3340-6.
32. Tatsumi M, Cohade C, Nakamoto Y, Fishman EK, Wahl RL. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology (2005) 237:1038-45. doi:10.1148/radiol.2373040555
33. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol (2007) 25:579-86. doi:10.1200/JCO.2006.09.2403
34. National Comprehensive Cancer Network. Hodgkin Lymphoma. NCCN v2 (2012). Available at: http://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf
35. National Comprehensive Cancer Network. Non-Hodgkin Lymphoma. NCCN v3 (2012). Available at: http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf
36. Partridge S, Timothy A, O'Doherty MJ, Hain SF, Rankin S, Mikhaeel G. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin disease: influence on patient management in a single institution. Ann Oncol (2000) 11:1273-9. doi:10.1023/A:1008368330519
37. Pelosi E, Pregno P, Penna D, Deandreis D, Chiappella A, Limerutti G, et al. Role of whole body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non-Hodgkin lymphoma. Radiol Med (2008) 113:578-90. doi:10.1007/s11547-008-0264-7
38. Rigacci L, Vitolo U, Nassi L, Merli F, Gallamini A, Pregno P, et al. Positron emission tomography in the staging of patients with Hodgkin's lymphoma: a prospective multicentric study by the Intergruppo Italiano Linfomi. Ann Hematol (2007) 86:897-903. doi:10.1007/s00277-007-0356-9
39. Wirth A, Seymour JF, Hicks RJ, Ware R, Fisher R, Prince M, et al. Fluorine-18 flurordeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med (2002) 112:262-8. doi:10.1016/S0002-9343(01)01117-2
40. Munker R, Glass J, Griffeth LK, Sattar T, Zamani R, Heldmann M, et al. Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease. Ann Oncol (2004) 15:1699-704. doi:10.1093/annonc/mdh426
41. Raanani P, Shasha Y, Perry C, Metser U, Naparstek E, Apter S, et al. Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? Ann Oncol (2006) 17:117-22. doi:10.1093/annonc/mdj024
42. Rodríguez-Vigil B, Gómez-León N, Pinilla I, Hernández-Maraver D, Coya J, Martín-Curto L, et al. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low dose PET/CT. J Nucl Med (2006) 47:1643-8.
43. Kabickova E, Sumerauer D, Cumlivska E, Drahokoupilova E, Nekolna M, Chanova M, et al. Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin's disease. Eur J Nucl Med Mol Imaging (2006) 33:1025-31. doi:10.1007/s00259-005-0019-9
44. Elstrom RL, Leonard JP, Coleman M, Brown RK. Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. Ann Oncol (2008) 19:1770-3. doi:10.1093/annonc/mdn282
45. Brix G, Lechel U, Glatting G, Ziegler SI, Münzing W, Müller SP, et al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med (2005) 46:608.
46. Pinilla I, Gómez-León N, Del Campo-Del Val L, et al. Diagnostic value of CT, PET and combined PET/CT performed with low-dose unenhanced CT and full-dose enhanced CT in the initial staging of lymphoma. Q J Nucl Med Mol Imaging (2011) 55:567-75.
47. Beal KP, Yeung HW, Yahalom J. FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. Ann Oncol (2005) 16:473-80. doi:10.1093/annonc/mdi093
48. Hoffmann M, Wöhrer S, Becherer A, Chott A, Streubel B, Kletter K, et al. 18F-fluoro-deoxy-glucose positron emission tomography in lymphoma of mucosa-associated lymphoid tissue: histology makes the difference. Ann Oncol (2006) 17:1761-5. doi:10.1093/annonc/mdl295
49. Chung R, Lai R, Wei P, Lee J, Hanson J, Belch AR, et al. Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International prognostic index. Blood (2007) 110:1278-82. doi:10.1182/blood-2007-01-070300
50. Campbell J, Seymour JF, Matthews J, Wolf M, Stone J, Juneja S. The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. J Eur J Haematol (2006) 76:473. doi:10.1111/j.1600-0609.2006.00644.x
51. Pakos EE, Fotopoulos AD, Ioannidis JP. 18F FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med (2005) 46:958-63.
52. Wu LM, Chen FY, Jiang XX, Gu HY, Yin Y, Xu JR. (18)F-FDG PET, combined FDG-PET/CT and MRI for evaluation of bone marrow infiltration in staging of lymphoma: a systematic review and meta-analysis. Eur J Radiol (2012) 8:303-11. doi:10.1016/j.ejrad.2010.11.020
53. Wang J, Weiss LM, Chang KL, Slovak ML, Gaal K, Forman SJ, et al. Diagnostic utility of bilateral bone marrow examination: significance of morphologic and ancillary technique study in malignancy. Cancer (2002) 94:1522-31. doi:10.1002/cncr.10364
54. Chen YK, Yeh CL, Tsui CC, Liang JA, Chen JH, Kao CH. F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis. Clin Nucl Med (2011) 36:553-9. doi:10.1097/RLU.0b013e318217aeff
55. Cheng G, Chen W, Chamroonrat W, Torigian DA, Zhuang H, Alavi A. Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients. Eur J Nucl Med Mol Imaging (2011) 38:1469-76. doi:10.1007/s00259-011-1815-z
56. Shaefer NG, Strobel K, Taverna C, Hany T. Bone involvement in patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med Mol Imaging (2007) 34:60-7. doi:10.1007/s00259-006-0238-8
57. Núñez R, Rini JN, Tronco GG, Tomas MB, Nichols K, Palestro CJ. Correlation of hematologic parameters with bone marrow and spleen uptake in FDG PET. Rev Esp Med Nucl (2005) 24:107-12.
58. Salaun PY, Gastinne T, Bodet-Milin C, Campion L, Cambefort P, Moreau A, et al. Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation? Eur J Nucl Med Mol Imaging (2009) 36:1813. doi:10.1007/s00259-009-1183-0
59. El-Galaly TC, d'Amore F, Mylam KJ, de Nully Brown P, Bøgsted M, Bukh A, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol (2012) 30:4508-14. doi:10.1200/JCO
60. Richardson SE, Sudak J, Warbey V, Ramsay A, McNamara CJ. Routine bone marrow biopsy is not necessary in the staging of patients with classical Hodgkin lymphoma in the 18F-fluoro-2-deoxyglucose positron emission tomography era. Leuk Lymphoma (2012) 53:381-5. doi:10.3109/10428194.2011.616613
61. Radford JA, Cowan RA, Flanagan M, Dunn G, Crowther D, Johnson RJ, et al. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin disease. J Clin Oncol (1988) 6:940-6.
62. Zinzani PL, Magagnoli M, Chierichetti F, Zompatori M, Garraffa G, Bendandi M, et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol (1999) 10:1181-4. doi:10.1023/A:1008327127033
63. Cremerius U, Fabry U, Neuerburg J, Zimny M, Osieka R, Buell U. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun (1998) 19:1055-63. doi:10.1097/00006231-199811000-00005
64. Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT. Leuk Lymphoma (2000) 2000(39):543-53. doi:10.3109/10428190009113384
65. Dittmann H, Sokler M, Kollmannsberger C, Dohmen BM, Baumann C, Kopp A, et al. Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma. Oncol Rep (2001) 8:1393-9.
66. Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG after first line chemotherapy in non-Hodgkins lymphoma: is ([18F]FDG PET a valid alternative to conventional diagnostic methods? J Clin Oncol (2001) 19:414-9.
67. Mikhaeel NG, Mainwaring P, Nunan T, Timothy AR. Prognostic value of interim and post treatment FDG-PET scanning in Hodgkin lymphoma [abstract]. Ann Oncol (2002) 13(Suppl 2):21.
68. Wiedmann E, Baican B, Hertel A, Baum RP, Chow KU, Knupp B, et al. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease. Leuk Lymphoma (1999) 34:545-51.
69. Hueltenschmidt B, Sautter-Bihl ML, Lang O, Maul FD, Fischer J, Mergenthaler HG, et al. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer (2001) 91:302-10. doi:10.1002/1097-0142(20010115)91:2<302::AID-CNCR1002>3.3.CO;2-W
70. Bishu S, Quigley JM, Bishu SR, Olsasky SM, Stem RA, Shostrom VK, et al. Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma. Leuk Lymphoma (2007) 48:1548-55. doi:10.1080/10428190701344915
71. Tateishi U, Tatsumi M, Terauchi T, Ishizawa K, Ogura M, Tobinai K. Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine: a multicenter study. Cancer Sci (2011) 102:414-8. doi:10.1111/j.1349-7006.2010.01802.x
72. Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet (2011) 377:42-51. doi:10.1016/S0140-6736(10)62175-7
73. Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A, et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol (2011) 29:3194-200. doi:10.1200/JCO.2011.35.0736
74. Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H, et al. Impact of [18F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Grouped'Etudes des Lymphomes de l'Adulte and GOELAMS. J Clin Oncol (2012) 30:4317-22. doi:10.1200/JCO.2012.43.0934
75. Brice P, Bouabdallah R, Moreau P, Divine M, André M, Aoudjane M, et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle. Bone Marrow Transplant (1997) 20:21-6. doi:10.1038/sj.bmt.1700838
76. Moskowitz CH, Yahalom J, Zelenetz AD, Zhang Z, Filippa D, Teruya-Feldstein J, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol (2010) 148:890-7. doi:10.1111/j.1365-2141.2009.08037.x
77. Smeltzer JP, Cashen AF, Zhang Q, Homb A, Dehdashti F, Abboud CN, et al. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant (2011) 11:1646-52. doi:10.1016/j.bbmt.2011.04.011
78. Moskowitz AJ, Yahalom J, Kewalramani T, Maragulia JC, Vanak JM, Zelenetz AD, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood (2010) 116:4934-7. doi:10.1182/blood-2010-05-282756
79. Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood (2012) 119:1665-70. doi:10.1182/blood-2011-10-388058
80. Sucak GT, Özkurt ZN, Suyani E, Yasar DG, Akdemir Öü, Aki Z, et al. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival. Ann Hematol (2011) 90:1329-36. doi:10.1007/s00277-011-1209-0
81. Schot B, van Imhoff G, Pruim J, Sluiter W, Vaalburg W, Vellenga E. Predictive value of early positron emission tomography in chemosensitive relapsed lymphoma. Br J Haematol (2003) 123:282-7. doi:10.1046/j.1365-2141.2003.04593.x
82. Schot BW, Zijlstra JM, Sluiter WJ, van Imhoff GW, Pruim J, Vaalburg W, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood (2007) 109:486-91. doi:10.1182/blood-2005-11-006957
83. Terasawa T, Dahabreh IJ, Nihashi T. Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis. Oncologist (2010) 15:750-9. doi:10.1634/theoncologist.2010-0054
84. Poulou LS, Thanos L, Ziakas PD. Unifying the predictive value of pretransplant FDG PET in patients with lymphoma: a review and meta-analysis of published trials. Eur J Nucl Med Mol Imaging (2010) 37:156-62. doi:10.1007/s00259-009-1258-y
85. Dickinson M, Hoyt R, Roberts AW, Grigg A, Seymour JF, Prince HM, et al. Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. Br J Haematol (2010) 150:39-45. doi:10.1111/j.1365-2141.2010.08162.x
86. Haw R, Sawka CA, Franssen E, Berinstein HL. Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma: a literature review. J Clin Oncol (1994) 12:1074-84.
87. Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica (2006) 91:475-81.
88. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol (2007) 25:3746-52. doi:10.1200/JCO.2007.11.6525
89. Zinzani PL, Tani M, Fanti S, Alinari L, Musuraca G, Marchi E, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol (2006) 17:1296-300. doi:10.1093/annonc/mdl122
90. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol (2005) 16:1160-8. doi:10.1093/annonc/mdi200
91. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood (2006) 107:52-9. doi:10.1182/blood-2005-06-2252
92. Zinzani PL, Rigacci L, Stefoni V, Broccoli A, Puccini B, Castagnoli A, et al. Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 atients. Eur J Nucl Med Mol Imaging (2012) 39:4-12. doi:10.1007/s00259-011-1916-8
93. Terasawa T, Lau J, Bardet S, Couturier O, Hotta T, Hutchings M, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol (2009) 27:1906-14. doi:10.1200/JCO.2008.16.0861
94. Moskowitz CH, Schöder H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol (2010) 28:1896-903. doi:10.1200/JCO.2009.26.5942
95. Cerci JJ, Pracchia LF, Linardi CC, Pitella FA, Delbeke D, Izaki M, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med (2010) 51:1337-43. doi:10.2967/jnumed.109.073197
96. Straus DJ, Johnson JL, LaCasce AS, Bartlett NL, Kostakoglu L, Hsi ED, et al. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood (2011) 117:5314-20. doi:10.1182/blood-2010-10-314260
97. Kostakoglu L, Schöder H, Johnson JL, Hall NC, Schwartz LH, Straus DJ, et al. Interim FDG pet imaging in CALGB 50203 trial of stageI/II non-bulky Hodgkin lymphoma: would using combined PET and CT criteria better predict response than each test alone? Leuk Lymphoma (2012) 53:2143-50. doi:10.3109/10428194.2012.676173
98. Barnes JA, LaCasce AS, Zukotynski K, Israel D, Feng Y, Neuberg D, et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. Ann Oncol (2011) 22:910-5. doi:10.1093/annonc/mdq549
99. Le Roux PY, Gastinne T, Le Gouill S, Nowak E, Bodet-Milin C, Querellou S, et al. Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. Eur J Nucl Med Mol Imaging (2011) 38:1064-71. doi:10.1007/s00259-011-1741-0
100. Dann EJ, Blumenfeld Z, Bar-Shalom R, Avivi I, Ben-Shachar M, Goor O, et al. 10-year experience with treatment of high and standard risk Hodgkin disease: six cycles of tailored BEACOPP, with interim scintigraphy, are effective and female fertility is preserved. Am J Hematol (2012) 87:32-6. doi:10.1002/ajh.22187
101. Avigdor A, Bulvik S, Levi I, Dann EJ, Shemtov N, Perez-Avraham G, et al. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma. Ann Oncol (2010) 21:126-32. doi:10.1093/annonc/mdp271
102. Markova J, Kahraman D, Kobe C, Skopalova M, Mocikova H, Klaskova K, et al. Role of [18F]-fluoro-2-deoxy-d-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. Leuk Lymphoma (2012) 53:64-70. doi:10.3109/10428194.2011.603444
103. Gallamini A, Patti C, Viviani S, Rossi A, Fiore F, Di Raimondo F, et al. Gruppo ItalianoTerapie Innovative nei Linfomi (GITIL) early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with interim-PET positive after two ABVD courses. Br J Haematol (2011) 152:551-60. doi:10.1111/j.1365-2141.2010.08485.x
104. Radford J, Barrington S, Councell N, Pettengell R, Johnson P, Wimperis J, et al. Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a 'negative' PET scan after 3 cycles ABVD. Results of the UK NCRI RAPID Trial 54th ASH Annual Meeting (2012). Abstract 547 p.
105. Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, et al. [18F]Fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood (2005) 106:1376-81. doi:10.1182/blood-2005-01-0272
106. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol (2005) 16:1514-23. doi:10.1093/annonc/mdi272
107. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol (2002) 13:1356-63. doi:10.1093/annonc/mdf256
108. Casasnovas RO, Meignan M, Berriolo-Riedinger A, Bardet S, Julian A, Thieblemont C, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood (2011) 118:37-43. doi:10.1182/blood-2010-12-327767
109. The Lymphoma Academic Research Organisation. GA in Newly Diagnosed Diffuse Large B Cell Lymphoma (GAINED) (NCT01659099) (2012). Available from: http://www.clinicaltrials.gov/ct2/show/NCT01659099?term=GAINED%2C+PET%2C+casasnovas&rank=1
110. Quddus F, Armitage JO. Salvage therapy for Hodgkin's lymphoma. Cancer J (2009) 15:161-3. doi:10.1097/PPO.0b013e3181a1438a
111. Engert A, Eichenauer DA, Dreyling M. Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2009) 20(Suppl 4):108-9. doi:10.1093/annonc/mdp144
112. Friedberg JW, Mauch PM, Rimsza LM, Fisher RI. Non-Hodgkin's lymphomas. 8th ed. In: DeVita VT, Lawrence TS, Rosenberg SA editors. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins (2008). p. 2098-166.
113. Terasawa T, Nihashi T, Hotta T, Nagai H. 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review. J Nucl Med (2008) 49:13-21. doi:10.2967/jnumed.107.039867
114. Goldschmidt N, Or O, Klein M, Savitsky B, Paltiel O. The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. Ann Hematol (2011) 90:165-71. doi:10.1007/s00277-010-1044-8
115. Zinzani PL, Stefoni V, Tani M, Fanti S, Musuraca G, Castellucci P, et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol (2009) 27:1781-7. doi:10.1200/JCO.2008.16.1513
116. Lee AI, Zuckerman DS, Van den Abbeele AD, Aquino SL, Crowley D, Toomey C, et al. Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis. Cancer (2010) 116:3835. doi:10.1002/cncr.25240
117. Josting A, Diehl V. Current treatment strategies in early stage Hodgkin's disease. Curr Treat Options Oncol (2003) 4:297-305. doi:10.1007/s11864-003-0005-z
118. Cheson B. The case against heavy PETing. J Clin Oncol (2009) 11:1742-3. doi:10.1200/JCO.2008.20.1665
119. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging Subcommittee of International Harmonization Project in lymphoma. J Clin Oncol (2007) 25:571-8. doi:10.1200/JCO.2006.08.2305
120. Spaepen K, Stroobants S, Dupont P, Bormans G, Balzarini J, Verhoef G, et al. [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging (2003) 30:682-8. doi:10.1007/s00259-003-1120-6
121. Han HS, Escalón MP, Hsiao B, Serafini A, Lossos IS. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. Ann Oncol (2009) 2:309. doi:10.1093/annonc/mdn629
122. Kostakoglu L, Goldsmith SJ, Leonard JP, Christos P, Furman RR, Atasever T, et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer (2006) 107:2678-87. doi:10.1002/cncr.22276
123. Barrington SF, Qian W, Somer EJ, Franceschetto A, Bagni B, Brun E, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging (2010) 37:1824-33. doi:10.1007/s00259-010-1490-5
124. Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on interim-PET scan in lymphoma. Leukemia Lymphoma (2009) 50:1257-60. doi:10.1080/10428190903040048
125. Biggi A, Gallamini A, Chauvie S, Hutchings M, Kostakoglu L, Gregianin M, et al. International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med (2013) 54:683-90. doi:10.2967/jnumed.112.110890
126. Lin C, Itti E, Haioun C, Petegnief Y, Luciani A, Dupuis J, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med (2007) 48:1626-32. doi:10.2967/jnumed.107.042093
127. Diehl V, Re D, Harris NL, Mauch PM. Hodgkin lymphoma. 8th ed. In: DeVita VT, Lawrence TS, Rosenberg SA editors. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins (2008). p. 2167-213.
128. Hatt M, Cheze Le Rest C, Pradier O, Visvikis D. Automatic PET tumour delineation for patient's follow-up and therapy assessment. J Nucl Med (2009) 50:182.
129. Hatt M, Visvikis D, Albarghach NM, Tixier F, Pradier O, Cheze-le Rest C. Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology. Eur J Nucl Med Mol Imaging (2011) 38:1191-202. doi:10.1007/s00259-011-1755-7
130. Werner-Wasik M, Nelson AD, Choi W, Arai Y, Faulhaber PF, Kang P, et al. What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom. Int J Radiat Oncol Biol Phys (2012) 82:1164-71. doi:10.1016/j.ijrobp.2010.12.055
131. Song MK, Chung JS, Shin HJ, Lee SM, Lee SE, Lee HS, et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol (2012) 91:697-703. doi:10.1007/s00277-011-1357-2
132. Song MK, Chung JS, Shin HJ, Moon JH, Lee JO, Lee HS, et al. Prognostic value of metabolic tumor volume by PET/CT in primary gastrointestinal diffuse large B cell lymphoma. Cancer Sci (2012) 103:477-82. doi:10.1111/j.1349-7006.2011.02164.x